Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Evolocumab

View as PDF.

Public Citizen opposes Food and Drug Administration (FDA) approval of the new drug application for evolocumab for treatment of lipid disorders because there is insufficient information to evaluate the benefit-risk balance of the drug.